Literature DB >> 21921589

Distinctive blood eosinophilic phenotypes and cytokine patterns in eosinophilic esophagitis, inflammatory bowel disease and airway allergy.

Marianne Johnsson1, Mogens Bove, Henrik Bergquist, Mikael Olsson, Sven Fornwall, Karin Hassel, Agnes E Wold, Christine Wennerås.   

Abstract

Blood eosinophil numbers may be elevated in allergy, inflammatory bowel disease and eosinophilic esophagitis. The aim of this study was to examine whether circulating eosinophils display distinct phenotypes in these disorders and if different patterns of eosinophilic chemoattractants exist. Blood eosinophils from patients with symptomatic eosinophilic esophagitis (EoE; n = 12), ulcerative colitis (n = 8), airway allergy (n = 10) and healthy controls (n = 10) were enumerated and their surface markers analyzed by flow cytometry. Plasma levels of pro-eosinophilic cytokines were quantified in parallel. Data were processed by multivariate pattern recognition methods to reveal disease-specific patterns of eosinophil phenotypes and cytokines. EoE patients had higher numbers of eosinophils with enhanced expression of CD23, CD54, CRTH2 and CD11c and diminished CCR3 and CD44 expression. Plasma CCL5 was also increased in EoE. Although allergic patients had increased interleukin (IL)-2, IL-3, IL-5 and granulocyte macrophage colony-stimulating factor plasma concentrations, their blood eosinophil phenotypes were indistinguishable from those of healthy controls. Decreased eosinophilic expression of CD11b, CD18, CD44 and CCR3, but no distinctive pattern of eosinophil chemoattractants, characterized ulcerative colitis. We propose that eosinophils acquire varying functional properties as a consequence of distinct patterns of activation signals released from the inflamed tissues in different diseases.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21921589     DOI: 10.1159/000331326

Source DB:  PubMed          Journal:  J Innate Immun        ISSN: 1662-811X            Impact factor:   7.349


  34 in total

1.  IL-3 Maintains Activation of the p90S6K/RPS6 Pathway and Increases Translation in Human Eosinophils.

Authors:  Stephane Esnault; Elizabeth A B Kelly; Zhong-Jian Shen; Mats W Johansson; James S Malter; Nizar N Jarjour
Journal:  J Immunol       Date:  2015-08-14       Impact factor: 5.422

Review 2.  Biological therapies for eosinophilic gastrointestinal diseases.

Authors:  Joshua B Wechsler; Ikuo Hirano
Journal:  J Allergy Clin Immunol       Date:  2018-05-31       Impact factor: 10.793

3.  Dysphagia and health-related quality of life in patients with eosinophilic esophagitis: a long-term follow-up.

Authors:  Helen Larsson; Karin Bergman; Caterina Finizia; Leif Johansson; Mogens Bove; Henrik Bergquist
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-07-08       Impact factor: 2.503

Review 4.  Eosinophils and disease pathogenesis.

Authors:  Praveen Akuthota; Peter F Weller
Journal:  Semin Hematol       Date:  2012-04       Impact factor: 3.851

5.  Eosinophils from eosinophilic oesophagitis patients have T cell suppressive capacity and express FOXP3.

Authors:  C Lingblom; J Wallander; M Ingelsten; H Bergquist; M Bove; R Saalman; A Welin; C Wennerås
Journal:  Clin Exp Immunol       Date:  2016-12-06       Impact factor: 4.330

Review 6.  Activation states of blood eosinophils in asthma.

Authors:  M W Johansson
Journal:  Clin Exp Allergy       Date:  2014-04       Impact factor: 5.018

7.  Topical corticosteroids do not revert the activated phenotype of eosinophils in eosinophilic esophagitis but decrease surface levels of CD18 resulting in diminished adherence to ICAM-1, ICAM-2, and endothelial cells.

Authors:  Christine Lingblom; Henrik Bergquist; Marianne Johnsson; Patrik Sundström; Marianne Quiding-Järbrink; Mogens Bove; Christine Wennerås
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

Review 8.  Immunotherapeutic approaches for the treatment of eosinophilic esophagitis.

Authors:  Antonella Cianferoni; Jonathan M Spergel
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

9.  Utility of a Noninvasive Serum Biomarker Panel for Diagnosis and Monitoring of Eosinophilic Esophagitis: A Prospective Study.

Authors:  Evan S Dellon; Spencer Rusin; Jessica H Gebhart; Shannon Covey; Leana L Higgins; RoseMary Beitia; Olga Speck; Kimberly Woodward; John T Woosley; Nicholas J Shaheen
Journal:  Am J Gastroenterol       Date:  2015-03-17       Impact factor: 10.864

10.  Minimally invasive biomarker studies in eosinophilic esophagitis: A systematic review.

Authors:  Brittany T Hines; Matthew A Rank; Benjamin L Wright; Lisa A Marks; John B Hagan; Alex Straumann; Matthew Greenhawt; Evan S Dellon
Journal:  Ann Allergy Asthma Immunol       Date:  2018-05-16       Impact factor: 6.347

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.